Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Long-Term Follow-up of a Phase 1 Study of Ponatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML)

Moshe Talpaz, Jorge E. Cortes, Hagop Kantarjian, Neil P. Shah, Dale Bixby, Ian Flinn, Thomas O'Hare, PhD, Simin Hu, Victor M. Rivera, Tim Clackson, Christopher D. Turner, Frank G. Haluska, Brian J. Druker, Michael W. Deininger, Michael J. Mauro, MD

Blood (2014) 124 (21): 4558.

https://doi.org/10.1182/blood.V124.21.4558.4558

Published: 2014

Journal Articles

Ponatinib Safety and Efficacy in Japanese Patients with Philadelphia Positive Leukemia: Update of a Phase 1/2 Study

Taiichi Kyo, Arinobu Tojo, MD PhD, Kazuhito Yamamoto, Naoto Takahashi, Hirohisa Nakamae, Yukio Kobayashi, Tetsuzo Tauchi, Shinichiro Okamoto, Koichi Miyamura, Hiromi Iwasaki, MD PhD, Kiyohiko Hatake, MD PhD, Itaru Matsumura, Noriko Usui, Kumiko Yanase, Simin Hu, Tomoki Naoe, Kazuma Ohyashiki

Blood (2014) 124 (21): 5541.

https://doi.org/10.1182/blood.V124.21.5541.5541

Published: 2014

Journal Articles

Long-Term Anti-Leukemic Activity of Ponatinib in Patients with Philadelphia Chromosome-Positive Leukemia: Updated Results from an Ongoing Phase 1 Study

Michael W Deininger, MD, PhD, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Neil Shah, MD, PhD, Dale Bixby, MD, PhD, Michael J. Mauro, MD, Ian W. Flinn, MD, PhD, Thomas O'Hare, PhD, Simin Hu, PhD, David J. Dorer, Victor M. Rivera, PhD, Tim Clackson, PhD, Christopher D. Turner, MD, FAAP, Frank G Haluska, MD, PhD, Brian J. Druker, Moshe Talpaz, MD

Blood (2012) 120 (21): 3743.

https://doi.org/10.1182/blood.V120.21.3743.3743

Published: 2012

Journal Articles

Subset Analysis of Response to Treatment of Chronic Phase CML in a Phase 1 Study of Ponatinib in Refractory Hematologic Malignancies

Jorge E. Cortes, Hagop M. Kantarjian, Neil Shah, MD, PhD, Dale Bixby, MD, PhD, Michael J. Mauro, MD, Ian W. Flinn, MD, PhD, Thomas O'Hare, Simin Hu, PhD, Tim Clackson, PhD, Victor M. Rivera, PhD, Christopher D. Turner, MD, FAAP, Frank Haluska, MD, PhD, Brian J. Druker, Michael W. Deininger, Moshe Talpaz, MD

Blood (2011) 118 (21): 602.

https://doi.org/10.1182/blood.V118.21.602.602

Published: 2011

Journal Articles

A Phase 1 Trial of Oral Ponatinib (AP24534) In Patients with Refractory Chronic Myelogenous Leukemia (CML) and Other Hematologic Malignancies: Emerging Safety and Clinical Response Findings

Jorge Cortes, MD, Moshe Talpaz, MD, Dale Bixby, Michael Deininger, MD, PhD, Neil Shah, MD, PhD, Ian W. Flinn, MD, PhD, Michael Mauro, MD, Thomas O'Hare, PhD, Simin Hu, PhD, Rebecca Kan, Victor M. Rivera, PhD, Tim Clackson, PhD, Frank Haluska, MD, PhD, Hagop Kantarjian, MD

Blood (2010) 116 (21): 210.

https://doi.org/10.1182/blood.V116.21.210.210

Published: 2010

Journal Articles

A Phase 1 Trial of Oral AP24534 in Patients with Refractory Chronic Myeloid Leukemia and Other Hematologic Malignancies: First Results of Safety and Clinical Activity against T315I and Resistant Mutations.

Jorge Cortes, MD, Moshe Talpaz, MD, Michael Deininger, MD, PhD, Neil Shah, MD, PhD, Ian W Flinn, MD, Michael J. Mauro, MD, Thomas O'Hare, PhD, Natalie Spinos, Simin Hu, PhD, Lori Berk, Narayana Narasimhan, PhD, Victor M. Rivera, PhD, Tim Clackson, PhD, Frank Haluska, MD, PhD, Hagop M. Kantarjian, MD

Blood (2009) 114 (22): 643.

https://doi.org/10.1182/blood.V114.22.643.643

Published: 2009

NARROW

Long-Term Follow-up of a Phase 1 Study of Ponatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML)

Ponatinib Safety and Efficacy in Japanese Patients with Philadelphia Positive Leukemia: Update of a Phase 1/2 Study

Long-Term Anti-Leukemic Activity of Ponatinib in Patients with Philadelphia Chromosome-Positive Leukemia: Updated Results from an Ongoing Phase 1 Study

Subset Analysis of Response to Treatment of Chronic Phase CML in a Phase 1 Study of Ponatinib in Refractory Hematologic Malignancies

A Phase 1 Trial of Oral Ponatinib (AP24534) In Patients with Refractory Chronic Myelogenous Leukemia (CML) and Other Hematologic Malignancies: Emerging Safety and Clinical Response Findings

A Phase 1 Trial of Oral AP24534 in Patients with Refractory Chronic Myeloid Leukemia and Other Hematologic Malignancies: First Results of Safety and Clinical Activity against T315I and Resistant Mutations.

Email alerts

ASH Publications

American Society of Hematology

Long-Term Follow-up of a Phase 1 Study of Ponatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML)

Ponatinib Safety and Efficacy in Japanese Patients with Philadelphia Positive Leukemia: Update of a Phase 1/2 Study

Long-Term Anti-Leukemic Activity of Ponatinib in Patients with Philadelphia Chromosome-Positive Leukemia: Updated Results from an Ongoing Phase 1 Study

Subset Analysis of Response to Treatment of Chronic Phase CML in a Phase 1 Study of Ponatinib in Refractory Hematologic Malignancies

A Phase 1 Trial of Oral Ponatinib (AP24534) In Patients with Refractory Chronic Myelogenous Leukemia (CML) and Other Hematologic Malignancies: Emerging Safety and Clinical Response Findings

A Phase 1 Trial of Oral AP24534 in Patients with Refractory Chronic Myeloid Leukemia and Other Hematologic Malignancies: First Results of Safety and Clinical Activity against T315I and Resistant Mutations.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only